Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENT: Tislelizumab + Anlotinib + XELOX in Gastric Cancer
NCT04963088Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Maximum Tolerated Dose at 6 months and Objective Response Rate up to 18 months. Started Mar 2021; status: completed.
02
Drugs
tislelizumabanlotinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04963088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963088.